Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Nifuroxazide

Alternative Names: nifuroxazide, nifuroxazida
Clinical Status: Inactive
Latest Update: 2025-05-14
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Algeria | Bosnia | Bulgaria | Chile | Colombia | Croatia | Czech | Dominican Republic | Ecuador | Egypt | France | Greece | Hong Kong | Indonesia | Italy | Jordan | Korea | Lebanon | Mexico | Morocco | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | Singapore | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Cairo University
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Brain Diseases|Colitis, Ulcerative|Hepatic Encephalopathy|Liver Cirrhosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
NCT05988528

P3

Recruiting

Colitis, Ulcerative

2027-08-20

2023-08-24

Primary Endpoints|Treatments|Trial Status
CL (3202)

P3

Recruiting

Liver Cirrhosis|Hepatic Encephalopathy|Brain Diseases

2025-06-01

2025-05-15

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

Recent News Events

Date

Type

Title

05/01/2024

PubMed

 Utilizing machine learning to identify nifuroxazide as an inhibitor of ubiquitin-specific protease 21 in a drug repositioning strategy.

04/08/2024

PubMed

 Revolutionizing the Treatment of Idiopathic Pulmonary Fibrosis: From Conventional Therapies to Advanced Drug Delivery Systems.

03/13/2024

PubMed

 Determination of nitrofuran metabolites and nifurpirinol in animal tissues and eggs by ultra-high performance liquid chromatography-tandem mass spectrometry validated according to Regulation (EU) 2021/808.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions